Debra Patt, MD, PhD, MBA, executive vice president at Texas Oncology, discusses financial drivers affecting community oncology as well as new advances within cancer care that allow it to be treated as a chronic disease.
It's been a remarkable time of scientific discovery benefitting patients even as the landscape of community oncology has changed, said Debra Patt, MD, PhD, MBA, Executive Vice President at Texas Oncology.
Transcript
The Communty Oncology Alliance (COA) is celebrating its 20th year in 2023. How has community oncology changed in the past 20 years, and what are the greatest challenges ahead?
Community oncology has changed quite a bit in the last 20 years. What we've seen is a lot of financial drivers for consolidation that have made community oncology practices much fewer in number. In many states, there are very few community oncology practices at all, because many practices that have historically been community oncology practices, private practices, because of pressures in the market, have aligned with hospital systems. Even if the practice looks the same, the name on the shingle might be different. And the cost has gone up. There's been a tremendous shift in community-based cancer care.
Cancer care, though, has also gone through changes. You know, it's been a remarkable time of scientific discovery. We have immunotherapies that we didn't have 20 years ago. We have a tremendous number of targeted therapies. Today, about 30% of our patients are treated with oral therapies, even who have chronic and advanced cancer. That really makes cancer a chronic disease, much like hypertension, or diabetes, for many patients.
And so, instead of treating a patient and a brief episode for a short period of time, what happens is many patients, even with advanced cancer, are seeing their oncologist regularly to manage their cancer as a chronic disease. Our relationship with patients has changed. And how patients get treatment have has changed. These advances have really led most patients to be able to continue to function in their lives while they get treated with cancer. This means that they go to work at their jobs, they pick up their kids from soccer practice, they eat at their dinner table. Those are all exciting advances.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More